v3.26.1
SEGMENT (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Disaggregated Expense Information Included in the Consolidated Statements of Comprehensive Loss

The Group’s CODM is regularly provided with the following disaggregated expense information included in the consolidated statements of comprehensive loss:

 

 

Six Months Ended, June 30

 

 

 

2026

 

 

2025

 

 

 

NovaBridge

 

 

Visara

 

 

Total

 

 

NovaBridge

 

Segment revenue

 

$

—

 

 

$

—

 

 

$

—

 

 

$

—

 

Less:

 

 

 

 

 

 

 

 

 

 

 

 

Segment research and development expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Direct clinical development expenses

 

 

7,925

 

 

 

54

 

 

 

7,979

 

 

 

189

 

GIVA

 

 

7,925

 

 

 

—

 

 

 

7,925

 

 

 

202

 

Other oncology

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(13

)

Employee-related expenses

 

 

3,408

 

 

 

1,340

 

 

 

4,748

 

 

 

2,775

 

Other research and development expenses(1)

 

 

1,040

 

 

 

562

 

 

 

1,602

 

 

 

1,107

 

Segment administrative expenses(2)

 

 

23,135

 

 

 

3,281

 

 

 

26,416

 

 

 

8,309

 

Other segment items(3)

 

 

(2,832

)

 

 

(45

)

 

 

(2,877

)

 

 

(3,726

)

Segment net loss

 

$

(32,676

)

 

$

(5,192

)

 

$

(37,868

)

 

$

(8,654

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

165,464

 

 

$

25,173

 

 

$

190,637

 

 

$

165,404

 

 

 

 

(1)
Other research and development expenses include R&D services and other R&D overhead expenses.
(2)
Segment administrative expenses includes administrative employee benefit and other overhead expenses, and professional service fees.
(3)
Other segment items include interest income, foreign currency exchange gains and losses, gains on the sale of equity securities, and amortization and depreciation expense and other overhead expenses.